MANAGEMENT OF ASTHMATIC CHILDREN WITH DRY POWDER INHALER (BDP & SCG)

Dai Jiaxiong, Han Lianshu

Chang Zheng Hospital, Shanghai, China

Objective: The purpose of this study was to evaluate the efficacy and safety of dry powder inhaler beclomethasone dipropionate (BDP-DPI), combined with sodium cromoglycate (SCG-DPI) in the management of asthmatic children.

Methods: Since 1996, we have been first managing 74 cases of asthmatic children with BDP-DPI & SCG-DPI. BDP 200mg was inhaled twice daily for 2~3 weeks. Then inhaled 100mg BDP in the morning and 200mg at night combined with SCG 20mg three times daily. After 6 weeks the dosage of BDP was reduced gradually to zero within one year. Inhaled SCG alone for another 18 months. The clinical scores, the peak expiratory flow (PEF) and the expression of CD23 on peripheral lymphocyte were carried out.

Results: After followed up 4 years, except 3 cases relapsed, 71 cases (95.9%) were clinical controlled. PEF in the morning and at night increased from 162.53±43.2L/mim, 178.19±57.37L/mim to 223.23±28.56L/mim, 234.52±42.37L/mim respectively, P<0.05. The CD23⁺ percent of lymphocyte decreased from 10.23%±3.10% to 7.77%±3.22%, P<0.05. During inhaled SCG alone those above items were further improved.

Conclusion: Inhalation of BDP-DPI combination with SCG-DPI not only improved the treatment effect but also reduced BDP's dose and shortened the therapy course. The side effect of BDP induced by long term treatment can be remitted or even avoided.

0201